# Biotech Daily Digest — 2025-10-24

**42 items from 4 sources**

## Summary by Source

- Eli Lilly Press Releases: 2 items
- Endpoints News: 10 items
- Fierce Biotech: 7 items
- arXiv q-bio: 23 items


## Eli Lilly Press Releases

- **[Lilly to Acquire Adverum Biotechnologies](https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-adverum-biotechnologies)**  
  _Fri, 24 Oct 2025 08:30:00 -0400_  
  Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate

- **[Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial](https://investor.lilly.com/news-releases/news-release-details/lillys-baricitinib-delivered-near-complete-scalp-hair-regrowth)**  
  _Fri, 24 Oct 2025 06:45:00 -0400_  
  This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials  New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair


## Endpoints News

- **[Biogen pays $70M upfront to Vanqua Bio for immunology drug](https://endpoints.news/biogen-pays-70m-upfront-to-vanqua-bio-for-immunology-drug/)**  
  _Fri, 24 Oct 2025 14:29:40 +0000_  
  Biogen is giving C5aR1 another go.

 It's paying $70 million upfront to Vanqua Bio for exclusive global rights to the Chicago startup's preclinical C5aR1 antagonist dubbed VQ-201 and up to  ...

- **[Eli Lilly to seek Olumiant approval in adolescents with alopecia](https://endpoints.news/eli-lilly-to-seek-olumiant-approval-in-adolescents-with-alopecia/)**  
  _Fri, 24 Oct 2025 14:17:22 +0000_  
  Eli Lilly said Friday it plans to ask the FDA for a label expansion of its immunology drug Olumiant in adolescents with alopecia after successful long-term data.

 At one year of follow-up, Lilly said 54 ...

- **[Remix reveals first signs of tumor shrinkage with small molecule mRNA degrader](https://endpoints.news/remix-reveals-first-signs-of-tumor-shrinkage-with-small-molecule-mrna-degrader/)**  
  _Fri, 24 Oct 2025 14:00:54 +0000_  
  Remix Therapeutics, which is developing a new way to shut down the expression of cancer-causing genes, has seen the first signs of success in a rare salivary gland cancer.
 The company is developing small-molecule drugs ...

- **[Zai Lab shares Phase 1 data for lung cancer drug that could spar with Amgen’s Imdelltra](https://endpoints.news/zai-lab-shares-phase-1-data-for-lung-cancer-drug-that-could-spar-with-amgens-imdelltra/)**  
  _Fri, 24 Oct 2025 13:00:14 +0000_  
  Zai Lab on Friday reported updated early-stage data for its closely-watched ADC candidate that could compete with Amgen’s Imdelltra. Both drugs target the DLL3 protein and are designed to treat extensive-stage small cell lung cancer ...

- **[Post-Hoc: Why we tracked pharma’s private jet flights to DC](https://endpoints.news/post-hoc-why-we-tracked-pharmas-private-jet-flights-to-dc/)**  
  _Thu, 23 Oct 2025 17:02:11 +0000_  
  Earlier this year, I asked our reporter Max Bayer how we might keep track of pharma’s influence in Washington, DC.

 The usual way of tracking the relationship between corporations and the US government is through ...

- **[Merck KGaA to end API work at Irish plant after ‘strategic portfolio review’](https://endpoints.news/merck-kgaa-to-end-api-work-at-irish-plant-after-strategic-portfolio-review/)**  
  _Thu, 23 Oct 2025 16:24:04 +0000_  
  Merck KGaA is ending its API production work in Arklow, Ireland, and is proposing to shut down its factory at the end of 2028, a company spokesperson told Endpoints News.

 The company made the ...

- **[Lonza expects more CDMO contracts; Galderma's $650M US commitment](https://endpoints.news/lonza-expects-more-cdmo-contracts-galdermas-650m-us-commitment/)**  
  _Thu, 23 Oct 2025 15:55:08 +0000_  
  Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

 Lonza said it expects more contract signings for its CDMO business in ...

- **[Mikael Dolsten, Craig Crews team up for new molecular glue biotech](https://endpoints.news/mikael-dolsten-craig-crews-team-up-for-new-molecular-glue-biotech/)**  
  _Thu, 23 Oct 2025 15:27:01 +0000_  
  Pfizer's former CSO and a Yale University professor who's helped form multiple molecular glue startups have created a new biotech in the exciting field.



 Mikael Dolsten is the founding CEO and chair of Quarry Thera ...

- **[Icon warns of macro environment headwinds as Medpace maintains revenue momentum](https://endpoints.news/icon-warns-of-macro-environment-headwinds-as-medpace-maintains-revenue-momentum/)**  
  _Thu, 23 Oct 2025 15:18:35 +0000_  
  Icon said it is continuing to face project cancellations as customers are decreasing their early research spending. As for Medpace, the company said the worst might be over.

 Icon on Wednesday

- **[Tango to advance pancreatic cancer drug into Phase 3, raises $225M](https://endpoints.news/tango-to-advance-pancreatic-cancer-drug-into-phase-3-raises-225m/)**  
  _Thu, 23 Oct 2025 15:06:00 +0000_  
  Tango Therapeutics reported data for its experimental pancreatic cancer drug that are strong enough for the company to move it into a Phase 3 study while concurrently raising $225 million to get things going.  ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/lillys-buys-cash-strapped-adverum-its-phase-3-stage-eye-disease-gene-therapy" hreflang="en">Eli Lilly buys cash-strapped Adverum for its phase 3-stage eye disease gene therapy</a>](https://www.fiercebiotech.com/biotech/lillys-buys-cash-strapped-adverum-its-phase-3-stage-eye-disease-gene-therapy)**  
  _Oct 24, 2025 9:26am_  
  Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.

- **[<a href="https://www.fiercebiotech.com/biotech/biogen-beefs-immunology-pipeline-1b-deal-vanquas-pre-clinical-c5ar1-antagonist" hreflang="en">Biogen beefs up immunology pipeline with $1B deal for Vanqua's preclinical C5aR1 antagonist</a>](https://www.fiercebiotech.com/biotech/biogen-beefs-immunology-pipeline-1b-deal-vanquas-pre-clinical-c5ar1-antagonist)**  
  _Oct 24, 2025 8:31am_  
  Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist.

- **[<a href="https://www.fiercebiotech.com/medtech/labcorp-signs-carry-roches-newly-fda-cleared-alzheimers-blood-test" hreflang="en">Labcorp signs on to carry Roche's newly FDA-cleared Alzheimer's blood test</a>](https://www.fiercebiotech.com/medtech/labcorp-signs-carry-roches-newly-fda-cleared-alzheimers-blood-test)**  
  _Oct 24, 2025 8:23am_  
  Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes of cognitive decline for patients 55 years and older.

- **[<a href="https://www.fiercebiotech.com/biotech/sanofi-drops-rsv-vaccine-toddlers-after-phase-3-heads-failure" hreflang="en">Sanofi drops RSV vaccine for toddlers after phase 3 trial heads for failure</a>](https://www.fiercebiotech.com/biotech/sanofi-drops-rsv-vaccine-toddlers-after-phase-3-heads-failure)**  
  _Oct 24, 2025 4:42am_  
  Sanofi has dropped its respiratory syncytial virus vaccine for toddlers after the candidate underperformed in a phase 3 study.

- **[<a href="https://www.fiercebiotech.com/biotech/inhibrx-intends-fda-submission-after-antibody-scores-ph-2-win-rare-bone-cancer" hreflang="en">Inhibrx eyes FDA submission after phase 2 rare bone cancer win</a>](https://www.fiercebiotech.com/biotech/inhibrx-intends-fda-submission-after-antibody-scores-ph-2-win-rare-bone-cancer)**  
  _Oct 23, 2025 5:13pm_  
  Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved treatments, prompting the San Diego biotech to plot a submission to the FDA in the second half of 2026.

- **[<a href="https://www.fiercebiotech.com/biotech/regeneron-abandons-2seventybio-car-t-midway-through-phase-12-lymphoma-trial" hreflang="en">Regeneron does 180 on 2seventy lymphoma CAR-T, halting study and nixing further development</a>](https://www.fiercebiotech.com/biotech/regeneron-abandons-2seventybio-car-t-midway-through-phase-12-lymphoma-trial)**  
  _Oct 23, 2025 10:44am_  
  Regeneron has given up on a CAR-T candidate acquired from 2seventy last year, before it finished its phase 1/2 lymphoma study.

- **[<a href="https://www.fiercebiotech.com/biotech/arcturus-stock-halves-after-mrna-therapy-fails-evoke-efficacy-cystic-fibrosis-trial" hreflang="en">Arcturus' stock halves after mRNA therapy fails to evoke efficacy in cystic fibrosis trial</a>](https://www.fiercebiotech.com/biotech/arcturus-stock-halves-after-mrna-therapy-fails-evoke-efficacy-cystic-fibrosis-trial)**  
  _Oct 22, 2025 1:03pm_  
  In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis.


## arXiv q-bio

- **[Neurotremor: A wearable Supportive Device for Supporting Upper Limb Muscle Function](https://arxiv.org/abs/2510.19826)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19826v1 Announce Type: new 
Abstract: A sensor-fused wearable assistance prototype for upper-limb function (triceps brachii and extensor pollicis brevis) is presented. The device integrates surface electromyography (sEMG), an inertial measurement unit (IMU), and flex/force sensors on an M5StickC plus an ESP…

- **[Memory Effects in Disease Modelling Through Kernel Estimates with Oscillatory Time History](https://arxiv.org/abs/2510.19843)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19843v1 Announce Type: new 
Abstract: We design a linear chain trick algorithm for dynamical systems for which we have oscillatory time histories in the distributed time delay. We make use of this algorithmic framework to analyse memory effects in disease evolution in a population. The modelling is based on…

- **[Artificial Intelligence Powered Identification of Potential Antidiabetic Compounds in Ficus religiosa](https://arxiv.org/abs/2510.19867)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19867v1 Announce Type: new 
Abstract: Diabetes mellitus is a chronic metabolic disorder that necessitates novel therapeutic innovations due to its gradual progression and the onset of various metabolic complications. Research indicates that Ficus religiosa is a conventional medicinal plant that generates bi…

- **[Challenges and Recommendations in Establishing National Human Diversity Genomic Projects](https://arxiv.org/abs/2510.19869)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19869v1 Announce Type: new 
Abstract: Genomic approaches have revolutionized medical research, providing valuable insights into human physiology and disease. Despite major benefits from large collections of genomes, the lack of diversity in genomic data represents a significant challenge for advancing biome…

- **[Transforming Multi-Omics Integration with GANs: Applications in Alzheimer's and Cancer](https://arxiv.org/abs/2510.19870)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19870v1 Announce Type: new 
Abstract: Multi-omics data integration is crucial for understanding complex diseases, yet limited sample sizes, noise, and heterogeneity often reduce predictive power. To address these challenges, we introduce Omics-GAN, a Generative Adversarial Network (GAN)-based framework desi…

- **[Advancing Drug Development Through Strategic Cell Line and Compound Selection Using Drug Response Profiles](https://arxiv.org/abs/2510.19874)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19874v1 Announce Type: new 
Abstract: Early identification of sensitive cancer cell lines is essential for accelerating biomarker discovery and elucidating drug mechanism of action. Given the efficiency and low cost of small-scale drug screens relative to extensive omics profiling, we compared drug-response…

- **[Compressing Biology: Evaluating the Stable Diffusion VAE for Phenotypic Drug Discovery](https://arxiv.org/abs/2510.19887)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19887v1 Announce Type: new 
Abstract: High-throughput phenotypic screens generate vast microscopy image datasets that push the limits of generative models due to their large dimensionality. Despite the growing popularity of general-purpose models trained on natural images for microscopy data analysis, their…

- **[Modelling multiscale architecture of biofilm extracellular matrix and its role in oxygen transport](https://arxiv.org/abs/2510.19947)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19947v1 Announce Type: new 
Abstract: The extracellular matrix of biofilms presents a dense and intricate architecture. Numerous biophysical properties of the matrix surrounding microbial cells contribute to the heterogeneity of biofilms and their functions at the microscale. Previous mathematical models as…

- **[Drug-disease networks and drug repurposing](https://arxiv.org/abs/2510.19948)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19948v1 Announce Type: new 
Abstract: Repurposing existing drugs to treat new diseases is a cost-effective alternative to de novo drug development, but there are millions of potential drug-disease combinations to be considered with only a small fraction being viable. In silico predictions of drug-disease as…

- **[Fitness inference tested by in silico population genetics](https://arxiv.org/abs/2510.20500)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.20500v1 Announce Type: new 
Abstract: We consider populations evolving according to natural selection, mutation, and recombination, and assume that the genomes of all or a representative selection of individuals are known. We pose the problem if it is possible to infer fitness parameters and genotype fitnes…

- **[A flexible framework for structural plasticity in GPU-accelerated sparse spiking neural networks](https://arxiv.org/abs/2510.19764)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.19764v1 Announce Type: cross 
Abstract: The majority of research in both training Artificial Neural Networks (ANNs) and modeling learning in biological brains focuses on synaptic plasticity, where learning equates to changing the strength of existing connections. However, in biological brains, structural pl…

- **[Convexity of Neural Codes with Four Maximal Codewords](https://arxiv.org/abs/2510.20323)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.20323v1 Announce Type: cross 
Abstract: Place cells are neurons that act as biological position sensors, associated with and firing in response to regions of an environment to situate an organism in space. These associations are recorded in (combinatorial) neural codes, motivating the following mathematical…

- **[BadGraph: A Backdoor Attack Against Latent Diffusion Model for Text-Guided Graph Generation](https://arxiv.org/abs/2510.20792)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2510.20792v1 Announce Type: cross 
Abstract: The rapid progress of graph generation has raised new security concerns, particularly regarding backdoor vulnerabilities. While prior work has explored backdoor attacks in image diffusion and unconditional graph generation, conditional, especially text-guided graph ge…

- **[Deep Learning-Powered Electrical Brain Signals Analysis: Advancing Neurological Diagnostics](https://arxiv.org/abs/2502.17213)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2502.17213v2 Announce Type: replace 
Abstract: Neurological disorders pose major global health challenges, driving advances in brain signal analysis. Scalp electroencephalography (EEG) and intracranial EEG (iEEG) are widely used for diagnosis and monitoring. However, dataset heterogeneity and task variations hin…

- **[Generative diffusion model surrogates for mechanistic agent-based biological models](https://arxiv.org/abs/2505.09630)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2505.09630v3 Announce Type: replace 
Abstract: Mechanistic, multicellular, agent-based models are commonly used to investigate tissue, organ, and organism-scale biology at single-cell resolution. The Cellular-Potts Model (CPM) is a powerful and popular framework for developing and interrogating these models. CPM…

- **[A novel attention mechanism for noise-adaptive and robust segmentation of microtubules in microscopy images](https://arxiv.org/abs/2507.07800)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2507.07800v2 Announce Type: replace 
Abstract: Segmenting cytoskeletal filaments in microscopy images is essential for understanding their cellular roles but remains challenging, especially in dense, complex networks and under noisy or low-contrast image conditions. While deep learning has advanced image segment…

- **[On sources to variabilities of simple cells in the primary visual cortex: A principled theory for the interaction between geometric image transformations and receptive field responses](https://arxiv.org/abs/2509.02139)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2509.02139v3 Announce Type: replace 
Abstract: This paper gives an overview of a theory for modelling the interaction between geometric image transformations and receptive field responses for a visual observer that views objects and spatio-temporal events in the environment. This treatment is developed over comb…

- **[Quantifying Mental States in Work Environment: Mathematical Perspectives](https://arxiv.org/abs/2509.12162)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2509.12162v2 Announce Type: replace 
Abstract: We introduce a novel framework for quantifying mental and emotional states over time by combining virtual reality (VR) exposure with EEG recordings. Participants experienced a stress-inducing work scenario in VR, originally designed as a training tool for bank emplo…

- **[Aligning Transformers with Continuous Feedback via Energy Rank Alignment](https://arxiv.org/abs/2405.12961)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2405.12961v3 Announce Type: replace-cross 
Abstract: Searching through chemical space is an exceptionally challenging problem because the number of possible molecules grows combinatorially with the number of atoms. Large, autoregressive models trained on databases of chemical compounds have yielded powerful gene…

- **[JAMUN: Bridging Smoothed Molecular Dynamics and Score-Based Learning for Conformational Ensembles](https://arxiv.org/abs/2410.14621)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2410.14621v3 Announce Type: replace-cross 
Abstract: Conformational ensembles of protein structures are immensely important both for understanding protein function and drug discovery in novel modalities such as cryptic pockets. Current techniques for sampling ensembles such as molecular dynamics (MD) are computa…

- **[High-fidelity microsecond-scale cellular imaging using two-axis compressed streak imaging fluorescence microscopy](https://arxiv.org/abs/2412.16427)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2412.16427v2 Announce Type: replace-cross 
Abstract: Compressed streak imaging (CSI) is a computational imaging strategy that can acquire video at over 150 trillion frames per second. Despite this achievement, CSI faces challenges in detecting subtle intensity fluctuations in slow-moving, continuously illuminate…

- **[The Global Diffusion Limit for the Space Dependent Variable-Order Time-Fractional Diffusion Equation](https://arxiv.org/abs/2504.18787)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2504.18787v3 Announce Type: replace-cross 
Abstract: The diffusion equation and its time-fractional counterpart can be obtained via the diffusion limit of continuous-time random walks with exponential and heavy-tailed waiting time distributions. The space dependent variable-order time-fractional diffusion equati…

- **[A Selective Review of Modern Stochastic Modeling: SDE/SPDE Numerics, Data-Driven Identification, and Generative Methods with Applications in Biomathematics](https://arxiv.org/abs/2508.11004)**  
  _Fri, 24 Oct 2025 00:00:00 -0400_  
  arXiv:2508.11004v2 Announce Type: replace-cross 
Abstract: This review maps developments in stochastic modeling, highlighting non-standard approaches and their applications to biology and epidemiology. It brings together four strands: (1) core models for systems that evolve with randomness; (2) learning key parts of t…
